Investor Relations

Investor Relations

NYSE American Symbol SYN
Day Low/High
52 Week Low/High

Analyst Coverage

A.G.P. / Alliance Global PartnersJames Molloy

Maxim GroupJason McCarthy, Ph.D


Synthetic Biologics, Inc. is a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead clinical candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

View Profile


Our experienced management team holds an extensive clinical and commercial track record.

Investor Relations

Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
T: (303) 282-4800